Dr. John Campbell podkast

South Africa Omicron

0:00
26:49
Do tyłu o 15 sekund
Do przodu o 15 sekund
South Africa illuminates our futureUploaded 15-12-21https://ourworldindata.org/coronavirusSouth Africa, omicron situation and trendshttps://www.youtube.com/watch?v=p4EwCFqiJagCases, + 26,976Will increase for the next few weeksPositivity, 32.2%Deaths, + 54Professor Shabir MadhiGauteng Cases probably peakedMore transmissibility Combined with more population prior immunityThree to four weeks, down from 8 weeks in previous wavesUncoupling of cases severe disease and death rateDelta20,000 reported cases per day resulted in with 250 to 300 deaths OmicronDeaths 10 times lessOmicron not less virulentBut more community immunityAntibodies and T cellsOmicron is antibody evasiveT cytotoxic immunity is relatively well conservedThis is what is causing the uncouplingT cells come from infection and vaccinationGauteng, serum survey 73% have been infected by the virus, this has led to a lot of T cell immunityBoth will protect against severe diseasehttps://www.discovery.co.za/corporate/news-roomhttps://www.discovery.co.za/corporate/news-roomData from the first three weeks of the Omicron-driven wave in South AfricaData, spanning clinical records, vaccination records, pathology test results3.7 million peopleOmicron: A highly transmissible variant causing rapid community spreadThe Omicron variant of SARS-CoV-2Fuelling South Africa’s fourth waveGenomic Surveillance, Omicron over 90% of new infectionsHas displaced Delta variantThe Omicron-driven fourth wave has a significantly steeper trajectory of new infections relative to prior waves. National data show an exponential increase in both new infections and test positivity ratesVaccine effectiveness during the current Omicron waveSAMRC, n= 211,000 positive tests41% from adult members who had received two doses of the Pfizer78,000 of these COVID-19 test results were attributed to Omicron infectionsTo-date laboratory analysis has provided early insights into potential reduction in the effect of neutralising antibodies against the Omicron variantTwo doses of the PfizerTwo-dose Pfizer-BioNTech vaccination provides significant protection against hospitalisation in individuals with Omicron variant infection 33% protection against infection, relative to the unvaccinated(down from 80% protection against infection)70% protection against hospital admission(down from 93% with delta)Protection against hospital admission is maintained across all agesProtection against admission is consistent across a range of chronic illnessesDiabetes, hypertension, hypercholesterolemia, cardiovascular diseasesReinfection riskOmicron reinfection risk significantly higher compared to prior variantsOverall, the risk of re-infection (following prior infection) has increased over timeInfected with Delta, a 40% relative risk of reinfection with OmicronInfected with Beta, a 60% relative risk of reinfection with OmicronInfected in first wave, a 73% risk of reinfectionRisk of severe disease and hospitalisation significantly lower in Omicron infection compared to prior variantsThis lesser severity could, however, be confounded by the high seroprevalence levels of SARS CoV-2 antibodies in the general South African populationRisk of hospital admission among adults diagnosed with omicron is 29% lowerHospitalised adults, lower propensity to be admitted to high-care and intensive-care units, relative to prior wavesPreliminary observations on Omicron experience in childrenUnder 18 have a 20% higher risk of admission when infected with OmicronAlso increase in admissions for children under fiveMany are incidentally discovered in hospitalChildren were 51% less likely to test positive for COVID-19 relative to adults in the Omicron periodWhere children require admission for complications of COVID-19Bronchiolitis Learn more about your ad choices. Visit megaphone.fm/adchoices

Więcej odcinków z kanału "Dr. John Campbell"